Amgen Korea and Jeil Pharmaceutical said they signed an agreement to jointly sell Repatha (evolucumab), lipid-lowering drugs for atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia starting in June.Under the agreement, Amgen Korea and Jeil Pharmaceutical will conduct Repatha sale
CHICAGO, Ill. – Lilly’s VEGRF2 inhibitor Cyramza (ramucirumab) in combination with Keytruda (pembrolizumab) proved a survival benefit, compared with the existing chemotherapy-based standard of care, in patients with non-small cell lung cancer (NSCLC) whose disease progressed after the first-line imm
CHICAGO, Ill. – Pfizer’s first CDK4/6 inhibitor Ibrance (palbociclib), failed to extend overall survival (OS) in the first breast cancer treatment in the phase 3 PALOMA-2 study.However, the PALOMA-2 study was not designed to check OS data, and it did not include some survival data of patients during
Theragen Bio, a genetic analysis service and AI-based drug development company, said Tuesday that it would begin mass-producing pilot chips of 'Korean Chip 2.0' developed by the Korea Disease Control and Prevention Agency (KDCA).The National Institute of Health under the KDCA will conduct the 'Korea
Korea, designated by the WHO as a global biopharma manufacturing training hub, will start providing education on vaccine manufacturing for workers in the Asia-Pacific region.The Korean government and the Asia Development Bank (ADB) will jointly push for the training project.Korean National Institute
COPENHAGEN – With the 2022 European Alliance of Associations for Rheumatology (EULAR) Congress holding an in-person conference for the first time in two years, Korean professors also had the chance to show off their recent research in the field.Notably, Professor Jung Jae-hyun of the Department of R
COPENHAGEN – Bristol Myers Squibb’s deucravacitinib, a lupus treatment candidate, drew keen attention from global rheumatologists as the company unveiled the phase 2 study at the 2022 European Alliance of Associations for Rheumatology (EULAR) Congress Saturday.The phase 2 PAISLEY study evaluated deu
COPENHAGEN -- Celltrion aims to gain the upper hand in the fiercely competitive infliximab biosimilar market through direct selling Remsima SC, a top manager said Thursday."Currently, competition for infliximab biosimilars is cut-throat," Celltrion Vice President Choi Byoung-seo said during an inter
VUNO, a medical artificial intelligence solution company, will announce the research results of artificial intelligence-based liver cancer pathology at the American Society of Clinical Oncology (ASCO) annual conference from June 3-7.The AI-based digital pathology study targets liver cancer and disco
Samsung Bioepis presented new data on its adalimumab biosimilar, IMRALDI (SB5), at the European Alliance of Associations for Rheumatology (EULAR) 2022, in Copenhagen, Denmark, on Wednesday.The phase 1 clinical trial demonstrated pharmacokinetic (PK) equivalence between the new SB5 formulation and th
Starting next Wednesday, unvaccinated foreign arrivals won’t have to isolate themselves for a week like their vaccinated counterparts, officials said Friday.According to Central Disaster Management Headquarters, the government has decided to apply the quarantine exemption to unvaccinated entrants fr
PharmGen Science said it has signed a research and investment agreement with MediCloud, a company specializing in genomic analysis, to develop new drugs using human and microbiome genomic DNA NFT data analysis.NFT (Non-fungible Token) is a technology that uses blockchain to assign unique recognition
Korean pharmaceutical and biotech companies are using various open innovation tools to raise competitiveness in new drug development in the global market.In the past, Korean drugmakers conducted research in secrecy due to the risk of technology leakage. But now, they actively get technologies and bu
Hugel said Friday it obtained marketing approval for Letybo 50Unit, a botulinum toxin (BTX), from Poland’s Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL) on May 25.Earlier in 2019, Hugel and Austrian pharmaceutical firm Croma began phase 3 trials of the B
A U.S. study showed that telemedicine lowered the number of patient no-shows and increased the number of patient visits to primary care.In the Journal of the American Board of Family Medicine, a research team at the West Virginia University School of Medicine’s Family Medicine Department published a
COPENHAGEN -- A new analysis of the phase 3 clinical trial showed that Remsima SC (Ingredient: infliximab) made a significantly greater improvement in clinical outcomes compared to the intravenous (IV) in patients with rheumatoid arthritis (RA).The post-hoc study focused on confirming whether the nu
The health authorities have formed a task force of experts to work out criteria for lifting Covid-19 quarantine obligations and announce the results around June 17, officials said Thursday.Initially, the government had planned to remove Covid-19 rules, including the mandatory quarantine of confirmed
Myongji Hospital in Goyang has become the first medical institution in the northwest Gyeonggi Province to introduce a cooling balloon catheter ablation procedure to treat atrial fibrillation, a type of arrhythmia, the hospital said Thursday.A team led by Professors Hwang Ui-seok and Lee Jae-hyuk at
It is difficult to treat rare and intractable diseases because causes and treatment methods remain unclear. However, new therapeutics are emerging one after another to fight these diseases.So far, treatments for rare and intractable diseases have aimed to slow the disease progression or relieve symp
Newbase, a medical metaverse simulation platform, announced that it has attracted 4 billion won ($3.19 million) in Series A investments from BNH Investment, DevSisters Ventures, Timefolio Asset Management, and Digital Healthcare Partners (DHP).Newbase has been in the spotlight in various medical edu